|
|
|
Insider
Information: |
Frates James M |
Relationship: |
|
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
318,827 |
|
Indirect Shares
|
184,010 |
|
|
Direct
Value |
$2,148,775 |
|
|
Indirect Value
|
$3,642,655 |
|
|
Total
Shares |
502,837 |
|
|
Total
Value |
$5,791,430 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Alkermes Plc |
ALKS |
SVP, Alks Inc; CFO ALKS |
2020-05-14 |
91,828 |
2020-05-14 |
155,669 |
Premium* |
|
Sage Therapeutics, Inc. |
SAGE |
|
2021-06-16 |
1,035 |
2021-06-16 |
1,810 |
Premium* |
|
Amylyx Pharmaceuticals, Inc. |
AMLX |
|
2024-04-16 |
225,964 |
2024-04-16 |
26,531 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
262 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 11 of 11
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2017-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,500 |
130,654 |
0 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
|
2024-03-05 |
4 |
S |
$18.73 |
$33,560 |
D/D |
(1,792) |
134,784 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2016-12-07 |
4 |
OE |
$11.74 |
$336,409 |
D/D |
23,731 |
136,073 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2016-12-14 |
4 |
OE |
$11.74 |
$329,350 |
D/D |
25,000 |
137,342 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2017-11-08 |
4 |
AS |
$47.58 |
$996,009 |
D/D |
(20,932) |
144,039 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2017-11-29 |
4 |
AS |
$50.49 |
$1,057,249 |
D/D |
(20,932) |
144,039 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2018-02-17 |
4 |
D |
$67.26 |
$62,485 |
D/D |
(929) |
146,110 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2018-02-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
147,039 |
0 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
|
2024-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
152,035 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2017-11-08 |
4 |
OE |
$12.29 |
$257,254 |
D/D |
20,932 |
164,971 |
0 |
- |
|
ALKS |
Alkermes Plc |
SVP, Alks Inc; CFO ALKS |
|
2017-11-29 |
4 |
OE |
$12.29 |
$257,254 |
D/D |
20,932 |
164,971 |
0 |
- |
|
AMLX |
Amylyx Pharmaceuticals, I... |
Chief Financial Officer |
|
2024-04-16 |
4 |
A |
$0.00 |
$0 |
D/D |
91,180 |
225,964 |
0 |
- |
|
262 Records found
|
|
Page 11 of 11 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|